NASDAQ: EIKNEikon Therapeutics Inc Stock Ownership - Who owns Eikon Therapeutics?
Insider buying vs selling
Have Eikon Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Column Group IV GP LP | 10% Owner | 2026-02-06 | 1,437,323 | $18.00 | $25.87MBuy |
| Column Group IV GP LP | 10% Owner | 2026-02-06 | 49,556 | $18.00 | $892.01kBuy |
| Column Group IV GP LP | 10% Owner | 2026-02-06 | 630,881 | $18.00 | $11.36MBuy |
| Foresite Capital Management IV LLC | 10% Owner | 2026-02-04 | 55,555 | $18.00 | $999.99kBuy |
| Kenneth C. Frazier | Director | 2026-02-04 | 111,111 | $18.00 | $2.00MBuy |
| Lux Venture Partners V LLC | 10% Owner | 2026-02-04 | 138,888 | $18.00 | $2.50MBuy |
| Lux Venture Partners V LLC | 10% Owner | 2026-02-04 | 138,888 | $18.00 | $2.50MBuy |
| Josh Wolfe | Director | 2026-02-04 | 138,888 | $18.00 | $2.50MBuy |
| Josh Wolfe | Director | 2026-02-04 | 138,888 | $18.00 | $2.50MBuy |
EIKN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when EIKN insiders and whales buy or sell their stock.
EIKN Shareholders
What type of owners hold Eikon Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Column Group IV GP LP | 10.68% | 5,783,495 | $55.98M | Insider |
| Lux Venture Partners V LLC | 4.24% | 2,294,653 | $22.21M | Insider |
| Josh Wolfe | 4.24% | 2,294,653 | $22.21M | Insider |
| Roger M. Perlmutter | 2.73% | 1,475,856 | $14.29M | Insider |
| Foresite Capital Management IV LLC | 2.44% | 1,318,983 | $12.77M | Insider |
| Kenneth C. Frazier | 0.21% | 111,111 | $1.08M | Insider |
| Alfred Lloyd Bowie Jr. | 0.10% | 51,572 | $499.22k | Insider |
EIKN vs Biotech Stocks
Eikon Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.